Enlivex 過去の業績
過去 基準チェック /36
Enlivex は平均年間 83.1% の収益成長を遂げていますが、Biotechs 業界では年間 収益成長率 となっています。33.8% です。
主要情報
83.10%
収益成長率
64.16%
EPS成長率
| Biotechs 業界の成長 | 17.04% |
| 収益成長率 | n/a |
| 株主資本利益率 | 63.85% |
| ネット・マージン | n/a |
| 前回の決算情報 | 31 Dec 2025 |
最近の業績更新
更新なし
Recent updates
分析記事 • Oct 07
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...分析記事 • Jun 19
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Mar 01
We're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...分析記事 • Sep 13
Here's Why We're Watching Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Apr 04
We Think Enlivex Therapeutics (NASDAQ:ENLV) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Dec 13
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...分析記事 • Jul 25
Here's Why We're A Bit Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...分析記事 • Apr 05
Will Enlivex Therapeutics (NASDAQ:ENLV) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Nov 16
Is Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Sep 30
Enlivex Therapeutics: A Very Enticing Early-Stage Biotech
Summary Enlivex Therapeutics: The early results for Allocetra for sepsis (in humans) and solid tumors (in mice) look incredible. The share offering from 2021 shows a willingness to protect existing shareholders. All in all, the risk/reward profile justifies a small bet. Enlivex Therapeutics (ENLV) is a clinical stage pharmaceutical company developing a single drug candidate called Allocetra—an off-the-shelf, scalable, and affordable cell therapy which has been designed to reprogram macrophages in order to return them to their homeostatic state. It is currently being tested for life-threatening conditions such as sepsis and solid tumors, both as a standalone monotherapy and in combination with other therapies. The approach of ENLV is to target macrophages, a type of white blood cell that performs immune system functions such as removing dead cells from the body, engulfing and eliminating intrusive and harmful microbes that have entered the body, and activating other immune system cells. Sepsis is the body’s extreme response to an infection, whereby chemicals released in the blood to fight infection can trigger extreme inflammation in other parts of the body, potentially leading to organ failure. Like patients suffering from cancer, mortality rates for sepsis patients can be high. ENLV researchers believe that the macrophages of sepsis and solid tumor patients are out of their normal homeostatic state, and rather than engaging in anti-inflammation, pro-organ restoration, and anti-tumor activities, are instead engaging in pro-inflammation, pro-organ failure, and pro-tumor activities. The goal of Allocetra is to correct this imbalance and return macrophages to their homeostatic levels, which should reduce rates of drug resistance in patients and lead to better rates of disease resolution. Allocetra is a cell therapy, which refers to the practice of placing new cells into the patient’s body. After collecting cells from healthy donors, ENLV chemically modifies these donor cells using their proprietary process. The intent is to prompt the donor cells to send out an “eat me” signal, which is accomplished by expressing the biomarker phosphatidylserine, commonly known as “PtdSer.” Once the donor cells are placed into the patient’s body, the “eat me” signal attracts the macrophages in the surrounding inflamed area, which then engulf the donor cells. The engulfed donor cells then communicate with the macrophages while inside of them, and reprogram them in order to return them to their homeostatic state. ENLV’s method of communicating with the macrophages is proprietary, and forms the basis of their differentiated mechanism of action. To date, the only results in humans that we have for Allocetra were published on September 30, 2021 in the journal Frontiers In Immunology. As you can see in Table 1 on page 4, of the ten sepsis-treated patients, all of them lived, and their sepsis and organ dysfunction were resolved. Frontiers In Immunology; 9/30/21; pg 4 It does need to be pointed out that while the control group had a mortality rate of 27% (n=10/37), the phase 1b trial was run using a matched historical control. While this does not necessarily invalidate the results, using a matched historical control group is not as ideal as running a trial with simultaneous control and treatment groups. However, the currently-recruiting phase 2 sepsis trial will be a randomized, placebo-controlled, double-blind study. If the results can be replicated in phase 2, then this should alleviate investor concerns regarding the use of a historical control group in phase 1b. Thus far, all the solid tumor data we have is from animal models. But a quick glance at the results should make the potential impact of Allocetra very clear. ENLV ran the solid tumor study in mice suffering from mesothelioma, an aggressive and deadly form of cancer that occurs in the thin layer of tissue covering the majority of internal organs. In addition to Allocetra, the study incorporated the immune checkpoint inhibitor anti-CTLA4. The five groups analyzed were: mesothelioma (no treatment), mesothelioma + anti-CTLA4, mesothelioma + Allocetra (high dose), mesothelioma + anti-CTLA4 + Allocetra (low dose), and mesothelioma + anti-CTLA4 + Allocetra (high dose). On slide 30 of the company’s September 12, 2022 investor presentation, we can see clearly the encouraging results. By day 81, all eight of the mice in the no-treatment group had succumbed to the cancer. In the anti-CTLA4 group, only two of the eight mice were still alive, which was similar to the result of the high-dose Allocetra group (two of seven still alive). In the combo group of anti-CTLA4 + Allocetra (low dose), six of the nine mice were still alive. And finally, in the combo group of anti-CTLA4 + Allocetra (high dose), not only were all nine of the mice still alive, but all nine had a miraculous 100% cure rate. Company Presentation; 9/12/22; Slide 30 Any seasoned biotech investor knows that the number of companies that have shown very promising results in animal models that did not translate into the same results in humans are too numerous to count. Thus, these incredible results should be taken with a very large grain of salt. But a 100% survival rate and a 100% cure rate in the mouse model is startling, and clearly shows the synergistic potential of Allocetra when combined with another cancer-fighting agent. At a minimum, the mouse model results are certainly deserving of further investigation. On April 29, ENLV filed their 20-F Annual Report, which shows the number of ordinary shares beneficially owned by company insiders (it needs to be emphasized that the number of ordinary shares beneficially owned includes outstanding options and warrants to purchase ordinary shares). As of March 31, 2022, company insiders owned approximately 12% of the outstanding ordinary shares (see pg. 82), with Executive Chairman Shai Novak owning almost 7% on his own. 2021 20-F Annual Report Of Mr. Novak’s 1.3M potential shares, about 133K options have an exercise price of $2.69/share, and 174K have an exercise price of $3.66/share, with both exercise prices being below the current share price of about $4.00/share (as of September 29). However, Mr. Novak’s remaining options consist of 145K with an exercise price of $6.22/share, as well as 104K with an exercise price of $12.23/share, with both of these exercise prices being well above the current price. It would have been preferable if the exercise prices of all options would have been significantly higher than the current share price, as a low exercise price does not create a very high hurdle for management to reach in order to cash out. But for new shareholders at least, this level of potential insider ownership can be seen as a positive. One thing that investors should certainly like is the offering price of last year’s capital raise. The $10M offering announced on February 9, 2021 after-hours was for 500K shares at a price of $20.00/share. This came at a 17% discount to the previous day’s close of $24.00/share. However, the stock had closed at $13.05/share on February 2, and after positive COVID data was announced on February 3, proceeded to climb up to $24.00/share over the next few days. Viewed in this light, the offering price of $20.00/share and the 17% discount do not seem so unfair to existing shareholders. Furthermore, an expanded offering was announced later that same evening on February 9, 2021. The offering was expanded due to overwhelming demand, was also done at $20.00/share, and raised an additional $46M. They announced second quarter results on August 22, and as of June 30, had cash and cash equivalents of $63M, which management expects to last through 3Q2024. This works out to a quarterly cash burn of about $7M. With Allocetra development still being at such an early stage, it’s very unlikely that they will finance future clinical expenses via debt offerings.Seeking Alpha • Sep 06
Enlivex to gets US patent covering use of cell therapy Allocetra
Enlivex Therapeutics (NASDAQ:ENLV) said the U.S. Patent and Trademark Office issued a notice of allowance for patent application covering methods of using Allocetra to inhibit or reduce cytokine release syndrome in patients undergoing chimeric antigen receptor (CAR) T-cell therapy. The company expects the new patent — application number 15/551,284 — will be issued by the end of Q1 2023. The intellectual property protection is expected through at least 2036, the company said in a Sept. 6 press release. The company noted that Allocetra is being developed as a universal, off-the-shelf cell therapy aimed to reprogram macrophages into their homeostatic state.Seeking Alpha • Aug 29
Enlivex receives notice of allowance ffrom Japan for Allocetra derived from pooled donor cells
Enlivex Therapeutics (NASDAQ:ENLV) said on Monday the Japanese patent office issued a Notice of Allowance that will provide the company with added intellectual property protection through at least 2037, with claims covering the use of pooled donor cells as source materials for cell therapy, Allocetra. The Company expects the new patent to be issued in Japan by the second quarter of 2023. Enlivex is developing Allocetra as a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, and many others reprogram macrophages out of their homeostatic state.Seeking Alpha • Aug 22
Envilex Therapeutics reports Q2 results
Envilex Therapeutics press release (NASDAQ:ENLV): Q2 Net loss of $9.9M As of June 30, 2022, Enlivex had cash, cash equivalents, and short-term deposits of $62.5 million.分析記事 • Jul 08
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Seeking Alpha • Jul 06
Enlivex doses first patient in its phase 1/2 trial of peritoneal cancer combo treatment
Israel-based Enlivex Therapeutics (NASDAQ:ENLV) on Wednesday said the first patient had been dosed in its phase 1/2 clinical trial evaluating its cell therapy Allocetra in combination with chemotherapy to treat cancer of the peritoneum. ENLV stock +7.5% at $4.90 in afternoon trading. The early-to-mid stage trial is expected to enroll about 12 patients across four cohorts and will evaluate the safety and potential preliminary efficacy of Allocetra in combination with chemotherapy in peritoneal cancer patients. This is the initiation of the company's first oncology trial, according to ENLV CEO Oren Hershkovitz. The trial is taking place at Israel's Sheba Medical Center hospital.分析記事 • Mar 23
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Nov 25
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...分析記事 • Aug 12
We Think Enlivex Therapeutics (NASDAQ:ENLV) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Apr 29
We're Not Worried About Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn
Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Jan 11
Companies Like Enlivex Therapeutics (NASDAQ:ENLV) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • Nov 19
Do Institutions Own Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares?
If you want to know who really controls Enlivex Therapeutics Ltd. (NASDAQ:ENLV), then you'll have to look at the...収支内訳
収支内訳
Enlivex の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。
収益と収入の歴史
| 日付 | 収益 | 収益 | G+A経費 | 研究開発費 |
|---|---|---|---|---|
| 31 Dec 25 | 0 | 1,236 | 6 | 9 |
| 30 Sep 25 | 0 | -13 | 5 | 10 |
| 30 Jun 25 | 0 | -13 | 5 | 10 |
| 31 Mar 25 | 0 | -14 | 5 | 10 |
| 31 Dec 24 | 0 | -15 | 5 | 11 |
| 30 Sep 24 | 0 | -19 | 4 | 12 |
| 30 Jun 24 | 0 | -22 | 5 | 14 |
| 31 Mar 24 | 0 | -26 | 6 | 17 |
| 31 Dec 23 | 0 | -29 | 6 | 19 |
| 30 Sep 23 | 0 | -27 | 7 | 20 |
| 30 Jun 23 | 0 | -27 | 7 | 20 |
| 31 Mar 23 | 0 | -30 | 7 | 19 |
| 31 Dec 22 | 0 | -31 | 7 | 19 |
| 30 Sep 22 | 0 | -29 | 8 | 18 |
| 30 Jun 22 | 0 | -26 | 7 | 17 |
| 31 Mar 22 | 0 | -19 | 7 | 15 |
| 31 Dec 21 | 0 | -14 | 6 | 13 |
| 30 Sep 21 | 0 | -16 | 5 | 10 |
| 30 Jun 21 | 0 | -14 | 5 | 9 |
| 31 Mar 21 | 0 | -14 | 4 | 7 |
| 31 Dec 20 | 0 | -12 | 4 | 6 |
| 30 Sep 20 | 0 | -9 | 4 | 5 |
| 30 Jun 20 | 0 | -9 | 3 | 6 |
| 31 Mar 20 | 0 | -8 | 3 | 5 |
| 31 Dec 19 | 0 | -10 | 3 | 6 |
| 30 Sep 19 | 0 | -9 | 2 | 5 |
| 30 Jun 19 | 0 | -7 | 2 | 5 |
| 31 Mar 19 | 0 | -7 | 2 | 5 |
| 31 Dec 18 | 0 | -5 | 1 | 4 |
| 30 Sep 18 | 0 | -4 | 1 | 3 |
| 31 Dec 17 | 0 | -3 | 0 | 2 |
質の高い収益: ENLV 非現金収入 のレベルが高いです。
利益率の向上: ENLV過去に利益を上げました。
フリー・キャッシュフローと収益の比較
過去の収益成長分析
収益動向: ENLV過去 5 年間で収益を上げており、収益は年間83.1%増加しています。
成長の加速: ENLVは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。
収益対業界: ENLV昨年収益を上げたため、昨年の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。
株主資本利益率
高いROE: ENLVの 自己資本利益率 ( 63.9% ) は 傑出している と考えられます。
総資産利益率
使用総資本利益率
過去の好業績企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/21 10:17 |
| 終値 | 2026/05/21 00:00 |
| 収益 | 2025/12/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Enlivex Ltd. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1
| アナリスト | 機関 |
|---|---|
| Raghuram Selvaraju | H.C. Wainwright & Co. |